Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Inventory (2018 - 2025)

Akebia Therapeutics (AKBA) has disclosed Inventory for 8 consecutive years, with $15.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Inventory fell 3.9% to $15.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $15.6 million, a 3.9% decrease, with the full-year FY2025 number at $15.6 million, down 3.9% from a year prior.
  • Inventory was $15.6 million for Q4 2025 at Akebia Therapeutics, down from $18.6 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $45.2 million in Q3 2022 to a low of $15.6 million in Q4 2025.
  • A 5-year average of $26.7 million and a median of $21.2 million in 2022 define the central range for Inventory.
  • Peak YoY movement for Inventory: plummeted 63.77% in 2021, then surged 34.3% in 2022.
  • Akebia Therapeutics' Inventory stood at $36.6 million in 2021, then tumbled by 41.12% to $21.6 million in 2022, then fell by 27.25% to $15.7 million in 2023, then increased by 3.52% to $16.2 million in 2024, then dropped by 3.9% to $15.6 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Inventory are $15.6 million (Q4 2025), $18.6 million (Q3 2025), and $16.7 million (Q2 2025).